Your browser doesn't support javascript.
loading
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
Calle, Roberto A; Amin, Neeta B; Carvajal-Gonzalez, Santos; Ross, Trenton T; Bergman, Arthur; Aggarwal, Sudeepta; Crowley, Collin; Rinaldi, Anthony; Mancuso, Jessica; Aggarwal, Naresh; Somayaji, Veena; Inglot, Malgorzata; Tuthill, Theresa A; Kou, Kou; Boucher, Magalie; Tesz, Greg; Dullea, Robert; Bence, Kendra K; Kim, Albert M; Pfefferkorn, Jeffrey A; Esler, William P.
Affiliation
  • Calle RA; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Amin NB; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Carvajal-Gonzalez S; Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.
  • Ross TT; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Bergman A; Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.
  • Aggarwal S; Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.
  • Crowley C; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Rinaldi A; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Mancuso J; Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.
  • Aggarwal N; Aggarwal and Associates Limited, Brampton, ON, Canada.
  • Somayaji V; Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.
  • Inglot M; Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Wroclaw, Poland.
  • Tuthill TA; Dobrostan, Wroclaw, Poland.
  • Kou K; Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.
  • Boucher M; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Tesz G; Drug Safety Research and Development Global Pathology, Pfizer Worldwide Research and Development, Cambridge, MA, USA.
  • Dullea R; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Bence KK; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Kim AM; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Pfefferkorn JA; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
  • Esler WP; Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
Nat Med ; 27(10): 1836-1848, 2021 10.
Article in En | MEDLINE | ID: mdl-34635855
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acetyl-CoA Carboxylase / Enzyme Inhibitors / Diacylglycerol O-Acyltransferase / Non-alcoholic Fatty Liver Disease / Liver Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2021 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acetyl-CoA Carboxylase / Enzyme Inhibitors / Diacylglycerol O-Acyltransferase / Non-alcoholic Fatty Liver Disease / Liver Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: Nat Med Journal subject: BIOLOGIA MOLECULAR / MEDICINA Year: 2021 Type: Article Affiliation country: United States